EGFR and neoplasm: Indeed, FoxO3A, which is a well-known tumor suppressor gene, has emerged as a key downstream effector of various drugs used in tumor treatments, such as p38 inhibitors, cisplatin, paclitaxel, doxorubicin, imatinib, PI3K-Akt inhibitors, EGFR/HER2 inhibitors, and ionizing radiation [8].